CCO Treatment Updates
Right From the Start: Optimizing First-Line Antiretroviral Therapy
When to Start Antiretroviral Therapy
|
Module 1 of 4
|
Program Chair:
William G. Powderly, MD
- Kimberly Y. Smith, MD, MPH
|
|
|
 Kimberly Y. Smith, MD, MPH, reviews the current guidelines on when to start antiretroviral therapy and discusses how recent data may influence how the HIV community thinks about initiating HAART. Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the current recommendations on when to initiate antiretroviral therapy defined by the DHHS and IAS-USA guidelines
- Describe data from observational cohorts that have suggested benefits to initiating therapy at CD4+ cell counts > 350 cells/mm3
- Discuss the potential risks and benefits of earlier initiation of antiretroviral therapy
|
Update on Efficacy and Durability of Recommended Regimens for First-Line Therapy
|
Module 2 of 4
|
Program Chair:
William G. Powderly, MD
- Edwin DeJesus, MD, FACP, AAHIVS
|
|
|
Edwin DeJesus, MD, FACP, discusses the efficacy and durability data on the DHHS and IAS-USA recommended antiretrovirals for first-line therapy of HIV-infected individuals. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss how the efficacy data from clinical trials investigating recommended NRTIs may be utilized to choose initial antiretroviral therapy
- Recall the efficacy data from randomized clinical trials investigating recommended NNRTIs
- Summarize the efficacy results from clinical trials comparing PI-based regimens
- Describe the data from randomized clinical trials with patient follow-up ranging from 3-7 years
|
Safety and Tolerability of Recommended Regimens for First-Line Therapy
|
Module 3 of 4
|
Program Chair:
William G. Powderly, MD
|
|
Paul E. Sax, MD, discusses safety and tolerability data on each of the DHHS and IAS-USA recommended antiretrovirals for first-line therapy of HIV-infected individuals. Learning Objectives
Upon completion of this activity, participants should be able to:
- List the most common adverse events associated with each of the agents recommended by the DHHS and IAS-USA guidelines for use in first-line regimens
- Summarize data from clinical trials that have highlighted differences in the incidence of adverse events associated with recommended first-line regimens
- Discuss potential screening and patient selection strategies that may reduce the risk of development of certain adverse events in patients receiving first-line therapy
|
Aiming for Ease: The Importance of Regimen Convenience in Antiretroviral Therapy
|
Module 4 of 4
|
Program Chair:
William G. Powderly, MD
- Valerie E. Stone, MD, MPH
|
|
|
Valerie E. Stone, MD, MPH, discusses important factors in helping patients maintain adherence to antiretroviral therapy. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe data from cohort analyses that have determined levels of adherence during the recent HAART era
- Summarize patient behaviors that may influence adherence to prescribed medications
- Recount the pill burden and dosing schedule of the DHHS-recommended regimens for the initial treatment of HIV-infected individuals
|
CCO Slidesets
When to Start Antiretroviral Therapy
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 820 KB
|
Update on Efficacy and Durability of Recommended Regimens for First-Line Therapy
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 696 KB
|
Update on Safety and Tolerability of Recommended Regimens for First-Line Therapy
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 1,833 KB
|
Aiming for Ease: The Importance of Regimen Convenience In Antiretroviral Therapy
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 764 KB
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|